The Galapagos is an outdoor destination—visitors are typically on boats, in the water, or hiking—so good weather is important ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Galapagos NV is abandoning its small molecule roots to focus on cell therapy and at the same time splitting in two, with the spinout company, dedicated to acquiring a portfolio of assets, taking the ...

TD Cowen cut shares of Galapagos (NASDAQ:GLPG – Free Report) from a strong-buy rating to a strong sell rating in a report released on Thursday,Zacks.com reports. Other equities analysts also recently ...

Darwin Island in the Galapagos is home to Galapagos Sharks, massive schools of hammerhead sharks, and whale sharks, the biggest shark in the ocean. Divers come here from all around the world to swim ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...